Safety and Activity of Brentuximab Vedotin (BV) Plus Ifosfamide, Carboplatin, and Etoposide (ICE) for Relapsed/Refractory (Rel/Ref) Classical Hodgkin Lymphoma (cHL): Initial Results of a Phase I/II Trial

被引：30

作者：

Cassaday, Ryan D. ^{[1
,2
,3
]}

Fromm, Jonathan ^{[4
]}

Cowan, Andrew J. ^{[1
,2
,5
]}

Libby, Edward N., III ^{[1
,2
,5
]}

Philip, Mary ^{[6
]}

Behnia, Sanaz ^{[7
]}

Nartea, Margaret ^{[1
]}

Press, Oliver ^{[1
,2
,5
]}

Gopal, Ajay K. ^{[1
,2
,5
]}

机构：

[1] Fred Hutchinson Canc Res Ctr, Div Clin Res, 1124 Columbia St, Seattle, WA 98104 USA

[2] Seattle Canc Care Alliance, Seattle, WA USA

[3] Univ Washington, Sch Med, Div Hematol, Seattle, WA 98195 USA

[4] Univ Washington, Dept Pathol, Seattle, WA 98195 USA

[5] Univ Washington, Div Med Oncol, Seattle, WA 98195 USA

[6] Mem Sloan Kettering Canc Ctr, Immunol Program, 1275 York Ave, New York, NY 10021 USA

[7] Univ Washington, Dept Radiol, Seattle, WA 98195 USA

来源：

关键词：

D O I：

10.1182/blood.V128.22.1834.1834

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1834

引用

页数：6